Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations

Kienle, Gunver S.

doi:10.7453/gahmj.2012.1.1.016

Cited by 56 publications

(41 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 1200 documented patients he treated with Coley-Toxin 270 patients with nonoperable, often metastasized, cancer reportedly went into complete remission [97, 98]. In fact, about 80% of the reported spontaneous remissions from cancer are found to be related to infections [99] and the connection between febrile infection and spontaneous tumor regression is the most frequent association found in literature [86, 100–105].…”

Section: Discussionmentioning

confidence: 99%

Fever: Views in Anthroposophic Medicine and Their Scientific Validity

Martin

2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To conduct a scoping review to characterize how fever is viewed in anthroposophic medicine (AM) and discuss the scientific validity of these views. Methods. Systematic searches were run in Medline, Embase, CAMbase, and Google Scholar. Material from anthroposophic medical textbooks and articles was also used. Data was extracted and interpreted. Results. Most of the anthroposophic literature on this subject is in the German language. Anthroposophic physicians hold a beneficial view on fever, rarely suppress fever with antipyretics, and often use complementary means of alleviating discomfort. In AM, fever is considered to have the following potential benefits: promoting more complete recovery; preventing infection recurrences and atopic diseases; providing a unique opportunity for caregivers to provide loving care; facilitating individual development and resilience; protecting against cancer and boosting the anticancer effects of mistletoe products. These views are discussed with regard to the available scientific data. Conclusion. AM postulates that fever can be of short-term and long-term benefit in several ways; many of these opinions have become evidence-based (though still often not practiced) while others still need empirical studies to be validated, refuted, or modified.

show abstract

Section: Discussionmentioning

confidence: 99%

Fever: Views in Anthroposophic Medicine and Their Scientific Validity

Martin

2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Immunosuppression, in turn, may also facilitate opportunistic infections that may lead to M1 type macrophage polarization. In accordance with these data, infections might indeed be associated with spontaneous tumor regression [194]. The hypothesis is further supported by observations that gut flora is crucial for an effective chemotherapy [195].…”

Section: Therapeutic Interventions Targeting Tams and Mdscs Tuninmentioning

confidence: 59%

Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets

Szebeni¹,

Vízler

Nagy³

et al. 2016

IJMS

View full text Add to dashboard Cite

Since the observation of Virchow, it has long been known that the tumor microenvironment constitutes the soil for the infiltration of inflammatory cells and for the release of inflammatory mediators. Under certain circumstances, inflammation remains unresolved and promotes cancer development. Here, we review some of these indisputable experimental and clinical evidences of cancer related smouldering inflammation. The most common myeloid infiltrate in solid tumors is composed of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). These cells promote tumor growth by several mechanisms, including their inherent immunosuppressive activity, promotion of neoangiogenesis, mediation of epithelial-mesenchymal transition and alteration of cellular metabolism. The pro-tumoral functions of TAMs and MDSCs are further enhanced by their cross-talk offering a myriad of potential anti-cancer therapeutic targets. We highlight these main pro-tumoral mechanisms of myeloid cells and give a general overview of their phenotypical and functional diversity, offering examples of possible therapeutic targets. Pharmacological targeting of inflammatory cells and molecular mediators may result in therapies improving patient condition and prognosis. Here, we review experimental and clinical findings on cancer-related inflammation with a major focus on creating an inventory of current small molecule-based therapeutic interventions targeting cancer-related inflammatory cells: TAMs and MDSCs.

show abstract

“…However, its use was first reported back in the late 19th century, when surgeon William Coley demonstrated that the injection of killed bacterial products into inoperable sarcoma tissue led to the shrinkage of tumor [41]. He subsequently developed a mixed bacterial vaccine and was able to achieve long-term remissions in some patients with sarcoma and various tumor types [42, 43]. It was later recognized that cancer cells express tumor antigens that may stimulate cellular and/or humoral responses.…”

Section: Immunotherapymentioning

confidence: 99%

Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects

2016

View full text Add to dashboard Cite

Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care. Even more recently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines. Overall, these interventions have gradually changed the landscape of cancer management in general, and metastatic renal cell carcinoma (mRCC) in particular. This is exemplified by the recent United States Food and Drug Administration (USFDA) approval of nivolumab for patients with mRCC after failure of TKI therapy. In this review, we present a brief overview of the current management of mRCC, primarily the clear cell subtype (ccRCC), and discuss the major clinical trials and data on the immunotherapy in advanced or mRCC.

show abstract

Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations

Cited by 56 publications

References 86 publications

Fever: Views in Anthroposophic Medicine and Their Scientific Validity

Fever: Views in Anthroposophic Medicine and Their Scientific Validity

Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets

Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects

Contact Info

Product

Resources

About